A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study

Lutz E Lehmann†1, Malte Book*†1, Wolfgang Hartmann2, Stefan U Weber3, Jens-Christian Schewe3, Sven Klaschik3, Andreas Hoeft3 and Frank Stüber1

Address: 1University Department of Anaesthesiology and Pain Therapy, Inselspital, CH-3010 Bern, Switzerland, 2Department of Pathology, Bonn University, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany and 3Clinic and Policlinic for Anaesthesiology and Operative Intensive Care, Bonn University, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany

Email: Lutz E Lehmann - lutz.lehmann@insel.ch; Malte Book* - malte.book@dkf.unibe.ch; Wolfgang Hartmann - wolfgang.hartmann@uni-bonn.de; Stefan U Weber - Stefan.Weber@ukb.uni-bonn.de; Jens-Christian Schewe - jens-christian.schewe@ukb.uni-bonn.de; Sven Klaschik - sven.klaschik@ukb.uni-bonn.de; Andreas Hoeft - andreas.hoeft@ukb.uni-bonn.de; Frank Stüber - Frank.Stueber@insel.ch

* Corresponding author  †Equal contributors

Abstract

Background: Macrophage migration inhibitory factor (MIF) plays an important regulatory role in sepsis. In the promoter region a C/G single nucleotide polymorphism (SNP) at position -173 (rs755622) and a CATT5-8 microsatellite at position -794 are related to modified promoter activity. The purpose of the study was to analyze their association with the incidence and outcome of severe sepsis.

Methods: Genotype distributions and allele frequencies in 169 patients with severe sepsis, 94 healthy blood donors and 183 postoperative patients without signs of infection or inflammation were analyzed by real time PCR and Sequence analysis. All included individuals were Caucasians.

Results: Genotype distribution and allele frequencies of severe sepsis patients were comparable to both control groups. However, the genotype and allele frequencies of both polymorphisms were associated significantly with the outcome of severe sepsis. The highest risk of dying from severe sepsis was detectable in patients carrying a haplotype with the alleles -173 C and CATT7 (p = 0.0005, fisher exact test, RR = 1,806, CI: 1.337 to 2.439).

Conclusion: The haplotype with the combination of the -173 C allele and the -794 CATT7 allele may not serve as a marker for susceptibility to sepsis, but may help identify septic patients at risk of dying.

Background

Macrophage Migration Inhibitory Factor (MIF) is a cytokine widely expressed in both immune and non-immune cells playing an essential role in the pathophysiology of host immune and inflammatory responses [1,2]. After discovery for its name-giving activity of inhibiting the random migration of peritoneal macrophages [3], MIF was rediscovered as a hormone-like factor secreted by macrophages, anterior pituitary cells, and endothelial cells activating both macrophages and T-lymphocytes [4-7]. MIF was shown to be induced rather than suppressed by glucocorticoids and to have a capacity to override the...
anti-inflammatory and immunosuppressive effects of glucocorticoids [8]. Moreover, MIF was discovered to be involved in the regulation of cell membrane expression of TLR4, which mediates recognition of Gram-negative bacteria [9]. Also, MIF was shown to influence immuno-regulatory processes by indirectly affecting the transcriptional activity of nuclear transcription factor AP-1 [10]. The role of MIF in Gram-negative sepsis was reviewed by Roger and colleagues [11] and updated by Emonts and co workers [12]. Circulating concentrations of MIF were markedly elevated in children and adults who had severe sepsis or septic shock [12]. Circulating MIF levels are correlated with sepsis severity scores, presence of shock, disseminated intravascular coagulation, urine output, blood pH, and lactate and cytokine levels [12]. Moreover, high levels of circulating MIF are associated with a fatal outcome [12,13].

Consequently, MIF has been a relevant candidate gene for investigation in inflammatory disease and studies focusing on elucidation of MIF gene expression have been undertaken. Two functionally relevant promoter polymorphisms of the MIF gene have been described. A single nucleotide polymorphism (SNP) was identified in the untranslated 5’ region of the MIF gene at position -173 consisting of a G to C transition (rs755622) [14]. Moreover, a tetranucleotide (CATT)5-8 repeat was found at position -794 [14]. Functional studies of both polymorphic sites have revealed altered MIF protein expression in vitro. Donn and co workers reported about the functional relevance of the -173 promoter SNP [16], whereas Baugh and co workers detected the -794 microsatellite and reported about the influence of the number of CATT repeats on the promoter activity [15]. In a large study Radstake and co workers reported the association of the -173 C allele and the -794 CATT microsatellite independently from each other with elevated circulating MIF levels in patients with rheumatoid arthritis [17]. Subsequently, higher MIF levels are correlated with more severe radiological joint damage [17].

The aim of this study was to evaluate the association of the MIF-173 G/C SNP and the MIF -794 CATT5-8 microsatellite with severe sepsis compared to healthy blood donors and patients with abdominal surgery but without signs of infection or inflammation. Secondly, an evaluation of the association of the MIF polymorphisms with the survival of severe sepsis patients was performed.

Methods
The investigation was in compliance with the Helsinki declaration. After approval of the local ethics committee and written informed consent of the patient or a legal guardian had been obtained, 169 Caucasian patients with the diagnosis of severe sepsis according to the consensus conference [18] were included in the study. SOFA [19] scores were calculated, IL-6 and Procalcitonin (PCT) plasma levels were measured after the patients fulfilled criteria for severe sepsis. All patients were treated according to the surviving sepsis campaign guidelines [20]. Staff physicians were blinded of the patient’s MIF genotype to avoid any bias in therapy. Two independent control groups were sampled, also: a) 183 Caucasian patients following major elective abdominal surgery without infectious or inflammatory complications and without post-operative ICU admission. b) 94 Caucasian healthy blood donors. All included individuals were Caucasians from Germany.

For genotyping of the MIF -173 promoter SNP 3.2 ml of whole blood were collected from each individual. DNA was prepared using the Flexi Gene DNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. Genotyping was done using a real-time PCR based system (LightCycler by Roche, Mannheim, Germany) with hybridization probes specific for the MIF -173 SNP. The PCR primer pair comprised of forward primer: 5’ GCCGTCATCTATGGGAAAGTAA, and reverse primer: 5’ CAGCAACGGCTGCTAA. The sequence for the MIF -173 SNP specific hybridization anchor probe was: 5’ GCGGGCTAGAAATCGCGCTGT. The sequence for the MIF -173 G/C SNP specific sensor probe was: 5’ GCTCCAGCCTGGTCGCTG. The anchor probe was phosphorylated at the 3’ end and carried a LightCycler Red 640 (Roche) dye at the 5’ end. The sensor probe was labeled by Fluorescein dye at the 5’ end. Primers and probes were designed in cooperation with TIB-MOLBIOL (Berlin, Germany) and manufactured by this company. In brief the PCR was done using 45 cycles of 5 sec denaturation at 95°C, 8 sec annealing at 60°C and 8 sec of primer extension at 72°C. Subsequent melting curve analysis for determination of the MIF genotype was done with an initial 20 sec denaturation at 95°C, followed by an 60 sec annealing at 50°C and a final ramp to 85°C with continuous fluorescence acquisition at a transition rate of 0.1°C/sec. Additionally, individual samples representing the G/G, G/C or C/C genotypes as analyzed by real-time PCR were also genotyped by DNA sequencing to control for the accuracy of the real-time PCR method. All controlled samples had matching results between real-time PCR and DNA sequencing.

Genotyping of the MIF -794 microsatellite was performed analyzing a 130-142 bp PCR fragment covering a known CATT repeat in the 5’untranslated region of the gene. Primers used were MIF forward 5-TGTCCTCTCTCTGTATGTGC 3, and MIF reverse 5-CACAATGGTAA CT CGGGG-3. The MIF reverse primer was 5-labeled with a fluorescent dye (5-FAM; MWG Biotech, Munich, Germany). The PCR program consisted of an initial denatur-
ation for 5 min at 94°C followed by 34 cycles of 35 sec
denaturation at 94°C, 40 sec annealing at 62°C, 40 sec
extension at 72°C and a final extension step of 10 min at
72°C. The reaction products were analyzed on a semiau-
tomated DNA sequencer (ABI 377) equipped with the
Genescan software (ABI, Darmstadt, Germany). The coin-
cidence of the -173 C allele and the -794 CATT7 microsat-
ellite was described as an inferred haplotype.

Statistical analysis of genotype distribution and allele fre-
quency was done by chi-square Test and Fischer’s exact
Test where applicable. The analysis of statistical differ-
ences of SOFA score and plasma levels (IL-6, PCT) was
done by Mann-Whitney-U test. Bonferroni correction was
applied for single marker analysis. Statistical significance
was assumed at p < 0.05. Statistical power (1- \(\beta\)) was calcu-
lated using binominal power calculation. The power cal-
culation for the -173 SNP and the -794 microsatellite
based on investigations by Amoli and Baugh [15,21]. The
relative risks of 2.1 and 1.56 were taken as a basis for effect
sizes of a -173 and a -794 allele, respectively. Both relative
risks were transferred from the mentioned publications
[15,21]. The prevalence of severe sepsis was estimated to
be 0.01. Using these preconditions the power of the pre-
sent results for the -173 C/C SNP and the -794 (CATT)\(_n\)
microsatellite was 98% and 87%, respectively. The linkage
disequilibrium of the two loci was assessed with the open
source application TASSEL2.1 [http://www.maizegenet-
ics.net]. The association between the C and the CATT\(_7\)
allele was assessed with a Fisher’s exact test.

**Results**

169 Patients with severe sepsis were studied (121 male
and 48 female). 94 healthy blood donors and 183
patients after abdominal surgery without post-operative
signs of infection or inflammation, without ICU admis-
sion and without case of death within the first postopera-
tive 28 days served as two separate control groups.
Furthermore, local wound infection rates reflected overall
infection rates of this group of patients. The baseline char-
acteristics of the both patient groups are outlined in Table
1. The mean age of healthy blood donors was 34 (18 to
56) and the female to male ratio was 37 to 57.

When dividing the severe sepsis patients in surviving (n =
91) and non-surviving patients (n = 78), mean SOFA
score, as well as IL-6 plasma levels were significantly
higher in non-surviving patients compared to survivors
(Table 2). However, PCT plasma levels were comparable
between the two groups (Table 2).

The allele CATT\(_8\) was neither detectable in the patients’
group nor in either of the control groups. The genotype
distribution and allele frequencies for the -173 SNP and
the -794 microsatellite were comparable between the
severe sepsis patients and the two control groups (p >
0.05, chi square test). There was no evidence of deviation
from the Hardy-Weinberg equilibrium in the patient and
control groups (p > 0.05, chi square test). Table 3 shows
the genotype and allele distribution of both polymor-
phisms in the three groups. The carriage of the allele -
173C was significantly associated with carriage of the -794
CATT\(_7\) microsatellite (Fisher’s exact test, p < 0.0001, RR =
8.398, CI: 6.187 to 11.40). Moreover, both polymor-
phisms are in linkage disequilibrium (D’ = 0.779).

The genotype and allele frequencies of both polymor-
phisms were significantly different between survivors and
non-survivors of severe sepsis (Table 3, -173 SNP geno-
type frequency: p = 0.0218, -173 SNP allele frequency: p =
0.0398, -794 microsatellite genotype frequency: p =
0.0016, -794 microsatellite allele frequency: p = 0.0174,
chi-square test and Fischer’s exact Test, respectively, all
Bonferroni corrected).

Carrying the C allele of the -173 SNP resulted in a relative
risk of 1.598 (CI: 1.165 to 2.193, p = 0.013, Fisher’s exact
test Bonferroni corrected, power: 1- \(\beta\) = 0.81) for a poor
outcome of severe sepsis. Independently from the -173
SNP, the carriage of the -794 CATT\(_7\) allele showed a rela-
tive risk of 1.839 (CI: 1.360 to 2.488, p = 0.0006, Fisher’s
test Bonferroni corrected, power: 1- \(\beta\) = 0.96) for

| Age (years)       | Severe Sepsis (n = 169) | Abdominal surgery without infection/inflammation (n = 183) | p-value |
|-------------------|------------------------|----------------------------------------------------------|---------|
| Female/Male (n)   | 58 (18 - 91)           | 56 (20 - 85)                                             | 0.16 *  |
| Source of infection |                        |                                                          |         |
| Pulmonary (n)     | 48 : 121               | 75 : 108                                                 | 0.014 **|
| Abdominal (n)     |                        |                                                          |         |
| Mortality (%)     | 46.2                   | 0                                                        |         |

Age is presented as mean and range of values. (n.a.: not applicable)
death due to severe sepsis compared to patients without allele CATT_7. The concomitance of the -173 allele C and the -794 allele CATT_7 as a haplotype was significantly associated with non-survival of severe sepsis (p = 0.0005, Fischer exact Test, RR = 1.806, CI: 1.337 to 2.439, power: 1-β = 0.91). Table 3 indicates the number of patients harboring the haplotype consisting of the -173 C and the -794 CATT_7 allele. Accordingly, these patients display the -173 SNP C/C or G/C genotype in combination with the -794 microsatellite 5/7, 6/7 or 7/7 genotype, respectively.

Table 4 indicates the association of the carriage of the -173 C allele and the -794 CATT_7 allele with fatal outcome in patients with severe sepsis which are grouped by the covariates "gender", "age", and "focus of infection". In the groups "female", "male", "≤ 60 years old", and non-pulmonary and non-abdominal focus, carriage of -173 C allele and -794 CATT_7 allele is associated with fatal outcome (table 4).

Discussion
The -794 MIF microsatellite is located in the promoter region and has functional relevance probably due to modified binding of nuclear transcription factors [22]. The relevance of the -794 microsatellite was assessed inconsistently with regard to analyzed cell types [15,22]. Just as well as the -794 microsatellite, the MIF -173 promoter SNP is of special interest because of its functional relevance. Donn and co workers detected increased promoter activity of the G allele compared to the C allele in an unstimulated lung epithelia cell line [16]. However, in the same work the authors reported about increased promoter activity of the C allele compared to the G allele in an also unstimulated T lymphoblast cell line [16]. The MIF plasma levels in -173 C carrying individuals were higher compared to non C carrying individuals [16]. Temple and co workers published about unstimulated and bacterial stimulated mononuclear cells in which allele -173 C occurrence resulted in decreased constitutive and inducible MIF mRNA levels [22]. This illustrates the complexity of the functional role of promoter polymorphisms in a comparatively simple ex vivo setting. Previous own results showed elevated MIF plasma levels in patients with severe sepsis as well as in patients with systemic inflammation compared to healthy controls [23].

Recent publications reported about the association of the -173 C allele with inflammatory diseases such as rheumatoid arthritis [17,24], inflammatory bowel diseases [25], and its clinical course [26]. The relevance of the C/C genotype was confirmed in Chinese patients with ulcerative colitis but not Crohn’s disease [27]. The -794 microsatellite is also related to inflammatory diseases such as atopy [28], asthma [29], and rheumatoid arthritis [15]. Finally, the correlation of the -173 C allele and the -794 CATT_7 allele as a haplotype with scleroderma [30], systemic lupus erythematosus [31] and with the susceptibility to psoriasis [32] was reported. A very recent publication reported about an association of -173 C allele carriage with lower 90 d mortality in a severe sepsis subgroup of patients with community-acquired pneumonia (CAP) which seems to be a contradiction to the presented results [33]. It has to be pointed out that Yende et al. reported a 90 day mortality rate of 27.2% in the severe sepsis subgroup which was lower compared to the 28 day mortality rate in the presented study (46.2%). This indicates that there might be elementary differences between both populations. Moreover, the independency of circulating MIF levels from the alleles is contradictory to previous reports [16]. Previous investigations in a Columbian population and Kenyan children showed the association (i) of the -173 C allele with tuberculosis and (ii) of the -173 C allele in combination with the -794 CATT_7 microsatellite with severe malarial anemia, respectively [34,35]. These findings seem to be in line with our results reporting deleterious effects of these markers in infectious diseases. However, as discussed by Yende and co workers these differences may reflect the clinical heterogeneity in patients with infectious diseases. Finally, Yende and co workers recruited their individuals in the northeastern United States, whereas our patients and controls were from western Germany origin. Although both investigations included Caucasians genetic differences might contribute to the divergent results.

An approach to explain our findings might be the increased promoter activity combined with increased MIF plasma levels as reported by Donn and co workers for the -173 C allele. This might increase cardiomyocyte apoptosis as reported in an animal sepsis model [36]. In addition, MIF was associated with dysregulated pituitary-

Table 2: Survivors and non-survivors of severe sepsis showed differences in SOFA score and IL-6 plasma level analyzed at the diagnosis of severe sepsis whereas PCT levels showed no significant differences (Mann-Whitney-U test).

|                  | Survivors (n = 91) | Non-Survivors (n = 78) | p-value |
|------------------|--------------------|------------------------|---------|
| SOFA Score       | 11 (7-20)          | 16 (14-22)             | 0.0256  |
| IL-6 (pg/ml)     | 1677 (15-31860)    | 6497 (264-70361)       | 0.0098  |
| PCT (ng/ml)      | 19.44 (9.45-46.49) | 22.08 (2.03-246.1)    | 0.052   |

Data are presented as mean and range of values.
Table 3: 173 and -794 genotype and allele distribution in the study population.

| Study groups                                      | Genotype | Allele | Genotype | Allele | Haplotypes |
|---------------------------------------------------|----------|--------|----------|--------|------------|
|                                                   | -173     |        | -794     |        |            |
|                                                   | G/G G/C  | C/C    | 5/5      | 6/6    | 7/7        |
|                                                   | p =      | p =    | p =      | p =    |            |
| Healthy Controls (n = 94)                          |          |        |          |        |            |
|                                                   | 63 28 3  | 0.67   | 154 34 0.859 | 4 25 8 39 18 0 | 0.123 41 121 26 0.045 |
| Abdominal surgery without infection or inflammation (n = 183) |          |        |          |        |            |
|                                                   | 123 54 6 |        | 300 66 7 | 55 7 75 35 4 | 76 240 50 |
| Severe sepsis (n = 169)                            | 106 60 3 |        | 272 66 15 | 50 18 54 28 4 | 98 186 54 |
| Survivors sev. Sepsis (n = 91)                     | 66 23 2 0.022 | 155 27 0.039 | 12 28 7 35 6 3 0.0016 | 59 104 19 0.0174 | 15 76 0.0005 |
| Non-Survivors sev. Sepsis (n = 78)                 | 40 37 1  | 117 39 3 | 22 11 19 22 1 | 39 82 35 32 46 |

The 169 patients with severe sepsis are separated by surviving or non-surviving in the lower two rows. Genotype and allele distribution of healthy controls, patients with abdominal surgery, and patients with severe sepsis were tested by chi square test. Survivors and non-survivors of severe sepsis were also tested by chi square and Fischer’s exact test where applicable, results were Bonferroni corrected. Incidence of the alleles -173 C and -794 CATT$^7$ was associated with non-surviving severe sepsis (p = 0.0005, Fisher exact Test, RR = 1.806, CI: 1.337 to 2.439).
adrenal function in sepsis [12] and fatal outcome of severe sepsis [37].

The relevance of MIF polymorphisms in patients with sepsis was addressed only by association studies, so far. Gao and co workers reported about an association of the -173 SNP genotype C/C with the incidence of sepsis in African Americans but not in European Americans [38]. However, because of the limited sample size of -173 C/C individuals in Gao’s investigation, this effect was assessed to be underpowered [38]. The number of individuals with the -173 C/C genotype in the present study is small as well and in the investigated Caucasian patients and control groups no significant association of the C/C genotype with the incidence of severe sepsis was detectable. It could be assumed, that different races might contribute to inconsistent associations due to different haplotype blocks. Gao and co workers reported about a haplotype in the European-descent American population which consists of the -173 promoter SNP, the promoter SNP rs9282783, the intron SNP rs2070777, the intergenic SNPs rs875643 and rs1007889 and the SNP rs2070767 which is located downstream of the 3’ untranslated region [38]. Our results showed linkage disequilibrium between the two polymorphisms. This is in line with findings from Temple and co workers as well as Yende and co workers [22,33]. In addition, Temple and co workers reported the significant association of the -173 C allele with the -794 CATT7 allele [22], which was supported by our data. Generally, investigations analysing candidate genes in selected phenotypes can not exclude the detection of significant associations which are functionally inconsiderable but are in linkage disequilibrium with possibly undetected causative variants. However, there is some evidence for a functional impact of the investigated polymorphisms as pointed out above.

In the sepsis patient sub groups female and male patients as well as patients with age ≤60 years and in patients with non-pulmonary or non-abdominal focus the haplotype was associated with poor outcome whereas in older patients and in the groups defined by the focus of sepsis it was not. Especially in the younger patient group the effect of genetic predisposition might be stronger because of the fewer incidences of other confounders influencing the outcome. For example serious co-existing diseases like pulmonary, vascular or heart disease are well known as important comorbidities in the elderly. The association in the sub group with non-abdominal, non-pulmonary sepsis focus might be caused by higher influence of genetic predisposition in a group which is least ill reflected by the lowest mortality rate.

It is a general limitation of association studies that it is impossible to decide whether the investigated SNP has functional meaning or is in linkage disequilibrium with another, yet not identified variant which might be causal for functional implications. To date there are numerous reports indicating associations of SNPs with the incidence, course or outcome in sepsis or severe sepsis patients [39-43]. Although the SNPs are located within genes and some of them showed functional relevance in an ex vivo setting it is not for sure the case in a complex situation as in vivo blood stream infection.

Another serious point frequently addressed to association studies is the statistical power. The design of the present study included 169 patients with severe sepsis, 94 healthy patients with non-severe sepsis and 190 healthy controls.

Table 4: Incidence of carrying the alleles -173 C and -794 CATT7 was associated with non-surviving severe sepsis in female and male patients, patients younger as 61 years old and patients with non-abdominal and non-pulmonary focus of sepsis.

| Patients with severe sepsis sub groups | Sup group | Mortality (%) | Association of allele carriage -173 C and -794 CATT7 and sub group status with fatal outcome |
|---------------------------------------|-----------|---------------|----------------------------------------------------------------------------------|
| Gender                                |           |               |                                                                                  |
| Female (n = 48)                       | 47.9      | 0.0135        | RR = 2.182, CI = 1.251 to 3.805                                                  |
| Male (n = 121)                        | 45.5      | 0.0267        | RR = 1.635, CI = 1.126 to 2.373                                                  |
| Age                                   |           |               |                                                                                  |
| ≤ 60 y (n = 84)                       | 41.7      | 0.0007        | RR = 2.400, CI = 1.541 to 3.737                                                  |
| > 60 y (n = 85)                       | 50.6      | 0.635         | RR = 1.159, CI = 0.7499 to 1.790                                                 |
| Focus of infection                     |           |               |                                                                                  |
| Pulmonal (n = 67)                     | 41.8      | 0.2312        | RR = 1.514, CI = 0.8559 to 2.679                                                 |
| Abdominal (n = 61)                    | 62.3      | 0.1734        | RR = 1.337, CI = 0.9228 to 1.937                                                 |
| Other/unknown (n = 41)                | 29.3      | 0.0066        | RR = 3.818, CI = 1.527 to 9.549                                                  |

RR: Relative risk; CI: Confidence interval
controls and 183 surgical patients without infectious complications. 91 patients with severe sepsis survived and 78 patients died. Based on the allele, genotype and haplotype frequencies, on the fraction of non-surviving patients and on the genotype relative risks the statistical power of the significant associations were 81%, 96% and 91%, respectively. The relative risks of -173 and -794 alleles and genotypes reported by Baugh and Amoli [15,21] showed that the two polymorphisms have considerable high effect sizes for certain phenotypes. Our results confirmed these findings. The relative risks for poor outcome of the two polymorphisms and combination of both were 1.6, 1.84 and 1.80. This effect size was in line with the data published by Baugh and Amoli [15,21].

Conclusion
The present study investigated for the first time the association of the MIF -173 promoter SNP and the MIF -794 CATT5-8 microsatellite with the incidence and outcome of severe sepsis by the comparison with two control groups. Our data indicate that neither alleles or genotypes of the -173 SNP variant nor of the -794 microsatellite were associated with the incidence of severe sepsis. However, at positions -173 and -794 alleles and genotypes were associated with survival of severe sepsis when analyzed separately as well as analyzed as a haplotype. Especially in the sub group of patients ≤60 years old and in patients with non-abdominal and non-pulmonary sepsis focus the association with poor outcome was pronounced. Of note, the common observation in both groups was the decreased mortality rate compared to the entire severe sepsis group. Therefore, in patients with severe sepsis and especially in younger patients with other than abdominal or pulmonary focus the MIF-173 G/C SNP and the -794 CATT5-8 microsatellite may not serve as markers for susceptibility to sepsis, but may well contribute to identify those septic patients at risk of dying.

List of Abbreviations
AP-1: Activator protein-1; CI: Confidence interval; ICU: Intensive care unit; IL-6: Interleukin-6; MIF: Macrophage migration inhibitory factor; n.a.: not applicable; PCR: Polymerase chain reaction; PCT: Procalcitonin; RR: Relative risk; SNP: Single nucleotide polymorphism; SOFA: Sequential Organ Failure Assessment; TLR4: Toll like receptor 4.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LEL planned the study, recruited patients, performed genotyping and drafted the manuscript. MB performed statistical calculations, wrote the manuscript, contributed to patient inclusion and study design. WH contributed to patient inclusion and study design, performed genotyping and drafted the manuscript. SUW contributed to patient inclusion, data analysis and drafted the manuscript. JCS contributed to patient inclusion and study design and drafted the manuscript. SK contributed to patient inclusion, genotyping and drafted the manuscript. AH contributed to study design, statistical calculations and drafted the manuscript. FS planned the study, supervised genotyping and statistical calculations, coordinated the study and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Sabine Mering for expert technical assistance with the genotyping assay.

References
1. Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-S35.
2. Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
3. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1976, 56:72-77.
4. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Genss D, Donnelly T, Bucala R: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1993, 93:7849-7854.
5. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelker W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759.
6. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
7. Nishihira J, Koyama Y, Mizuye Y: Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998, 10:199-205.
8. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
9. Roger T, David J, Glauser MP, Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001, 414:920-924.
10. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentscher A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapsneriotu A, Grell M, Finkemeier D, Brunner H, Bernhagen J: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through JAM1. Nature 2000, 408:211-216.
11. Roger T, Glauser MP, Calandra T: Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J Endotoxin Res 2001, 7:456-460.
12. Emonts M, Sweep FC, Grebenczichkov N, Geurts-Moetsap A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazeltz JA, Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44:1321-1328.
13. Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang AY: Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock 2007, 27:503-506.
14. Donn RP, Shelley E, Ollier WE, Thomson W: A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001, 44:1782-1785.
15. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R: A functional promoter polym...
phism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. *Arthritis Rheum* 2003, 48:1454-1463.

20. Evalue T, Colaco C, Lopes FP, de Andrade Júnior, Dias MG, Neto CA, Carvalho AD, Monteiro ES, Assis OA, Valarino JI: Association between MIF polymorphism and risk of coronary artery disease. *J Mol Med* 2007, 85:525-533.

21. Fei BY, Lv HX, Yang JM, Ye ZY: Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese Han population. *Gyakime* 2008, 41:44-47.

22. Hizawa N, Yamaguchi E, Takahashi D, Nishihira J, Nishimura M: Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy. *Am J Respir Crit Care Med* 2004, 169:1014-1018.

23. Inoue Y, Ghan S, Leng L, McDonald C, Kong P, Baugh J, Lane SJ, Craft J, Nishihira J, Donnelly SC, Zhu Z, Bucala R: Role for macrophage migration inhibitory factor in asthma. *Proc Natl Acad Sci USA* 2005, 102:14410-14415.

24. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, Hayes MD, Bucala R: Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. *Arthritis Rheum* 2006, 54:3661-3669.

25. Sanchez E, Gomez LM, Lopez-Neovot MA, Gonzalez-escrig MF, Koeleman BP, Martin J: Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. *Genes Immun* 2006, 7:433-436.

26. Doi DP, Pietro D, Jury F, Richards HL, Worthington J, Ray DW: Griffiths CE. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. *J Invest Dermatol* 2004, 21:484-487.

27. Yende S, Angus DC, Kong L, Kellum JA, Weissfeld L, Ferrell R, Finegold D, Carter M, Leng L, Peng ZY, Bucala R: The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. *FASEB* J 2009, 23:2403-2411.

28. Gomez LM, Sanchez E, Ruiz-Narvaez EA, Lopez-Neovot MA, Anaya JM, Martin J: Macrophage migration inhibitory factor gene influences the risk of developing tuberculosis in West African and Colombian populations. *Tissue Antigens* 2007, 70:28-33.

29. Awadare GA, Martinson JJ, Were T, Ouma C, Davenport GC, Ong’echa JM, Wang W, Leng L, Ferrell RE, Bucala R, Perkins DJ: MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. *J Infect Dis* 2009, 200:629-637.

30. Dhanantwari P, Nadaraj S, Kennessey A, Chowdhury D, Al-Abd Y, Miller EJ, Ojamaa K: Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. *Biochem Biophys Res Commun* 2008, 371:298-303.

31. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. *Shock* 2004, 22:18-29.

32. Gao L, Flores C, Fan-MA, Siller MJ, Moitra J, Moreno L, Wadganorkar R, Simon B, Brower R, Severnansky J, Tudor RM, Maloney JP, Moss M, Shanholzt C, Yates CR, Meduri GU, Ye SQ, Barnes KC, Garcia JG: Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. *Transf Res* 2007, 150:18-29.

33. Shalhub S, Junker CE, Imahara SD, Mindrinos MN, Dissanaike S, O’Keefe GE: Variation in the TLR4 gene influences the risk of organ failure and shock posttrauma: a cohort study. *J Trauma* 2008, 64:115-122.

34. Sipahi T, Kuybulu A, Ozturk A, Akar N: Protein Z G79A Polymorphism in Patients With Severe Sepsis. *Gin Appl Thromb Hemost* 2009 [http://cat.sagepub.com/cgi/content/abstract/107602960930010v1]

35. Russell JA, Wellman H, Walley KR: Protein C rs20659912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. *Hum Genet* 2008, 123:661-663.

36. Henckaerts L, Nielsens KR, Steffenrns R, Van SK, Mathieu C, Giulietti A, Wouters PJ, Milants I, Vanhorebeek I, Langouche L, Vermeire S, Ong’echa JM, Wang W, Leng L, Ferrell RE, Bucala R, Perkins DJ: Macrophage migration inhibitory factor polymorphism TNF (-308) is associated with susceptibility to meningococcal sepsis, but not with lethality. *Crit Care Med* 2009, 37:1237-1240.